Cognitive Impairment Secondary to Chemotherapy
An increasing body of literature supports the existence of cognitive impairment associated with standard-dose chemotherapy (Ahles & Saykin, 2001 ). The lay term for this treatment-related effect is "chemo brain" (Jansen et al., 2005) . Retrospective trials estimate an incidence ranging from 17%-75% (Wefel, Lenzi, Theriault, Davis, & Meyers, 2004) . Wefel et al. conducted the first longitudinal, prospective trial and evaluated the effects of standard-dose adjuvant chemotherapy in a small sample of women with breast cancer (N = 18). Neurocognitive testing was performed at baseline, six months (approximately three weeks from completion of therapy), and one year following the completion of chemotherapy. More than 60% of participants exhibited a decline in cognitive performance from baseline at the six-month evaluation. Nearly 50% of those subjects demonstrated cognitive improvement at the one-year evaluation.
Cognitive impairment has been demonstrated in patients receiving standard-dose chemotherapy for lymphoma. Ahles et al. (2002) compared survivors of Hodgkin disease (n = 31) and non-Hodgkin lymphoma (n = 27) with survivors of breast cancer (n = 35). Similar incidence This material is protected by U.S. copyright law. To purchase quantity reprints, e-mail reprints@ons.org. For permission to reproduce multiple copies, e-mail pubpermissions@ons.org.
